CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis

BMC Gastroenterology

Chin-Cheng Lee²  Chung-Wei Lee³  Chao-Sheng Liao¹  Yenn-Hwei Chou¹  Chih-Ming Ou Yang¹  Ching-Shya Yong¹ 

[1]Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, No.95, Wen Chang Road, Shih Lin District, Taipei City, 11120, Taiwan

[2]Department of Pathology, Shin Kong Wu Ho-Su Memorial Hospital, No.95, Wen Chang Road, Shih Lin District, Taipei City, 11120, Taiwan

[3]Department of Biological Engineering, Massachusetts Institute of Technology, Massachusetts, USA

关键词: Recurrent gastric cancer;    Prognosis;    CD24;    CD44;   

Others  :  1121910
DOI  :  10.1186/1471-230X-12-95

 received in 2012-03-27, accepted in 2012-07-17,  发布年份 2012

【 摘 要 】

Background

To correlate CD44/CD24 expression with gastric cancer recurrence and prognosis. Gastric cancer is the second leading cause of cancer mortality due to the high recurrence rate, of which the molecular signature has not yet been identified.

Methods

We retrospectively reviewed the hospital records of patients with gastric cancer. Among 500 patients receiving curative resection, 95 patients had recurrence. Twenty patients from the recurrence group (95 patients) and 20 patients from the non-recurrence group (405 patients) were randomly selected and identified as “study” and “control” groups, respectively. We reviewed patients’ histological study of CD44/CD24 expression by performing immunohistochemistry and recurrence rate.

Results

Study group had higher TNM stage (III-IV) than control group (80% vs. 25%, P = 0.001). Proportion of lymph node metastasis was significantly higher in study group than that in control group (90% vs. 45%, P = 0.002), and proportion of patients with 5 or more metastatic lymph nodes was also significantly higher in study group than in control group (45% vs. 15%, P = 0.007). Univariate analysis revealed no difference in risk of gastric cancer recurrence between CD44+ and CD44- patients (OR = 1.00, 95% CI: 0.29-3.45, P =1.000). CD24+ patients showed no greater significance of gastric cancer recurrence than CD24- patients (OR = 1.86, 95% CI: 0.52-6.61, P = 0.339). After adjusting for other risk factors, the association of CD44 expression (aOR = 0.66, 95% CI: 0.10-4.26, P = 0.658), CD24 expression (aOR = 0.09, 95% CI: 0.01-1.35, P = 0.081) or combined (CD44/CD24) with gastric cancer recurrence were not significant.

Conclusion

Neither individual expression of CD24 or CD44, nor combined expression of CD44/CD24 was associated with recurrence of gastric carcinoma.

【 授权许可】

   
2012 Yong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
• [2]Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y: Risk factors which predict pattern of recurrence after curative surgery for patient with advanced gastric cancer. Surg Oncol 1992, 1:341-346. [PMID: 1341269
• [3]Samson PS, Escovidal LA, Yrastorza SG, Veneracion RG, Nerves MY: Re-study of gastric cancer: analysis of outcome. World J Surg 2002, 26:428-433.
• [4]Resende C, Thiel A, Machado JC, Ristimäki A: Gastric cancer: Basic aspects. Helicobacter 2011, 16(Suppl 1):38-44.
• [5]Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Badve S, Nakshatri H: CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8:R59-[PMID: 17062128. BioMed Central Full Text
• [6]Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H: Prevalence of CD44+/CD24/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
• [7]Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Sima HR, Esmaili-Shandiz E, Hosseinnezhad H, Taghizadeh-Kermani A, Moaven O, Bahrani M: Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 2008, 14:6376-6381. PMID: 19009655
• [8]Gallatin WM, Weissman IL, Butcher EC: A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983, 13:30-34.
• [9]Idzerda RL, Carter WG, Nottenburg C, Wayner EA, Gallatin WM, St John T: Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc Nat Acad Sci 1989, 86:4654-4658.
• [10]Stamenkovic I, Aruffo A, Amiot M, Seed B: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyalouronate-bearing cells. EMBO J 1991, 10(2):343-348.
• [11]Darwish NS, Kim MA, Change MS, Lee HS, Lee BL, Kim YI, Kim WH: Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat 2004, 36:298-302.
• [12]Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 Expression Is a Novel Prognostic Factor in Diffuse-Type Gastric Adenocarcinoma. Ann Surgl Oncol 2007, 14:2748-2758. PMID: 17680316
• [13]Hong RL, Lee WJ, Shun CT, Chu JS, Chen YC: Expression of CD44 and its clinical implication in diffuse- and intestinal-type gastric adenocarcinomas. Oncology 1995, 52:334-339.
• [14]Kennel SJ, Lankford TK, Foote LJ, Shinpock SG, Stringer C: CD44 expression on murine tissues. J Cell Sci 1993, 104:373-382.
• [15]Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D: Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009, 24:37-41.
• [16]Qiao XT, Gumucio DL: Current molecular markers for gastric progenitor cells and gastric cancer stem cells. J Gastroenterol 2011, 46:855-865. PMID: 21626457
• [17]Zhang C, Li C, He F, Cai Y, Yang H: Identification of CD44 + CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol 2011, 137:1679-1686. [PMID: 21882047
• [18]Bektas S, Bahadir B, Ucan BH, Ozdamar SO: CD24 and Galectin-1 expressions in adenocarinoma and clinicopathologic significance. Pathol Oncol Res 2010, 16:569-577. [PMID: 20177845